p16INK4a Rabbit anti-Human, Mouse, Rat, Polyclonal, Invitrogen
Rabbit Polyclonal Antibody
Manufacturer: Invitrogen PA520379
A suggested positive control is mouse colon tissue lysate. PA5-20379 can be used with blocking peptide PEP-0496.The CDKN2A locus gives rise to 2 distinct transcripts from different promoters. The transcripts have been designated p16(INK4A) and p14(ARF). This chromosomal region undergoes a number of inversions, translocations, heterozygous deletions, and homozygous deletions in a variety of maligt cell lines including those from glioma, non-small cell lung cancer, leukemia, and melanoma. Deletion of the region containing CDKN2A is found in more than half of all melanoma cell lines. Conversely, transfection of CDKN2A suppressed the growth of two independent mesothelioma cell lines, suggesting that inactivation of the CDKN2 gene is an essential step in the etiology of maligt mesotheliomas. CDKN2A induces a G1 cell cycle arrest by inhibiting the phosphorylation of the Rb protein by the cyclin-dependent kinases CDK4 and CDK6. CDKN2A is expressed as at least three distinct isoforms.
|An 18 amino acid peptide from near the amino terminus of human CDKN2A.|
|Antigen affinity chromatography|
|Human, Mouse, Rat|
|Immunocytochemistry, Immunofluorescence, Immunohistochemistry, Western Blot|
|PBS with 0.02% sodium azide|
|P42771, P51480, Q8QZZ9|
|ARF, CDK4I, CDKN2, CMM2, INK4, INK4A, MLM, MTS-1, MTS1, P14, P14ARF, P16, P16-INK4A, P16INK4, P16INK4A, P19, P19ARF, TP16; CDK4 inhibitor p16-INK4; cell cycle negative regulator beta; cyclin-dependent kinase 4 inhibitor A; cyclin-dependent kinase inhibitor 2A; multiple tumor suppressor 1|
|Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C|
|1029, 12578, 25163|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok